GBT Insider Trading Activity and SEC Form 4 Filings
GBT insider trading summary
No open-market insider purchases or sales of Global Blood Therapeutics, Inc. (GBT) have been reported on SEC Form 4 in the past 12 months.
Latest GBT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 1, 2022 | Jeffrey S Farrow | Chief Financial Officer | Sell | $2.1M (31,441 @ $68.00) |
| Aug 18, 2022 | Nazila Habibizad | See Remarks | Sell | $314K (4,678 @ $67.19) |
| Jun 21, 2022 | Philip A. Pizzo | Director | Sell | $34K (1,260 @ $27.25) |
| Jun 21, 2022 | Dawn Svoronos | Director | Sell | $52K (1,908 @ $27.24) |
| Sep 9, 2021 | Scott W Morrison | Director | Sell | $145K (4,800 @ $30.21) |
| Jun 18, 2021 | Philip A. Pizzo | Director | Sell | $39K (1,065 @ $36.54) |
| Jun 18, 2021 | Dawn Svoronos | Director | Sell | $59K (1,609 @ $36.54) |
| May 10, 2021 | Eric Fink | Chief Human Resources Officer | Buy | $19K (500 @ $37.96) |
| Oct 5, 2020 | Eric Fink | Chief Human Resources Officer | Sell | $272K (4,532 @ $60.00) |
| Aug 20, 2020 | Brian Edwin Cathers | Chief Scientific Officer | Sell | $140K (2,200 @ $63.77) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.